Wouldn't it be reasonable to conclude that the reduction in...

Wouldn't it be reasonable to conclude that the reduction in death rates being seen in recent months would actually also correspond to a lower rate of infected people progressing to the ARDs severity levels required to be admitted into the MSB trial, I.e. the improvement in treatment avoids people becoming ventilator dependent. This might not necessarily lead to a proportionate reduction in death rate for the severe ventilator dependent target of this trial.

Are you altering your "survival" percentage for the MSB arm? Or are you pessimistically only attributing increased survival rates to the placebo(SoC) arm? If so it would require that any efficacy of Rem-L is totally overlapping the improvements in SoC, which is unlikely - though clearly very difficult to estimate.